Research
Supporting the science that will transform MCL outcomes.
Our Mission
Research is the engine of progress against mantle cell lymphoma. MCLA is committed to supporting targeted research that moves us closer to better treatments, longer remissions, and ultimately a cure. We fund, facilitate, and advocate for research that addresses the most pressing questions facing the MCL community.
Research Areas
Translational Research
Bridging the gap between laboratory discoveries and clinical practice — turning scientific insights into treatments that help patients.
Clinical Trials
Supporting clinical trial enrollment and education so more patients can access promising new treatments.
Collaborative Networks
Building connections between researchers, clinicians, and institutions to accelerate discovery and share knowledge.
Patient-Reported Outcomes
Advocating for research that measures what matters most to patients — quality of life, symptom burden, and real-world treatment experiences.
Research Priorities
Focusing on the science that will make the biggest difference for MCL patients.
MCLA prioritizes research that addresses the most critical unanswered questions in MCL and has the greatest potential to improve patient outcomes. Our priorities are shaped by input from our medical advisory board, researchers in the field, and the MCL patient community.
Overcoming Treatment Resistance
A major challenge in MCL is that most patients eventually develop resistance to current treatments. We prioritize research that investigates the mechanisms of resistance and identifies strategies to overcome or prevent it, including novel drug combinations and sequencing approaches.
Personalized Treatment Approaches
MCL is not one disease — it exists on a spectrum from indolent to highly aggressive. We support research that develops better tools for characterizing individual patients’ disease and matching them with the most effective treatment strategy, including biomarker-driven approaches.
Novel Therapeutic Targets
We support research exploring new molecular targets and treatment modalities for MCL, including next-generation targeted therapies, bispecific antibodies, cellular therapies beyond current CAR-T approaches, and combination strategies.
Minimal Residual Disease (MRD)
MRD testing — detecting very small numbers of remaining cancer cells — shows promise for guiding treatment decisions in MCL. We prioritize research that advances MRD assessment techniques and evaluates how MRD status can be used to tailor treatment duration and intensity.
Quality of Life Research
Treatment efficacy is only part of the equation. We advocate for research that measures and improves patient quality of life during and after treatment, including studies of long-term side effects, supportive care interventions, and patient-reported outcomes.
Support the science that will transform MCL outcomes.
Donate to Research →